Cullinan Oncology Stock Forecast - 8 Period Moving Average
| CGEM Stock | USD 12.54 0.32 2.62% |
The 8 Period Moving Average forecasted value of Cullinan Oncology LLC on the next trading day is expected to be 13.20 with a mean absolute deviation of 0.72 and the sum of the absolute errors of 38.19. Cullinan Stock Forecast is based on your current time horizon. Although Cullinan Oncology's naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Cullinan Oncology's systematic risk associated with finding meaningful patterns of Cullinan Oncology fundamentals over time.
Cullinan |
Cullinan Oncology 8 Period Moving Average Price Forecast For the 26th of November
Given 90 days horizon, the 8 Period Moving Average forecasted value of Cullinan Oncology LLC on the next trading day is expected to be 13.20 with a mean absolute deviation of 0.72, mean absolute percentage error of 0.94, and the sum of the absolute errors of 38.19.Please note that although there have been many attempts to predict Cullinan Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Cullinan Oncology's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Cullinan Oncology Stock Forecast Pattern
| Backtest Cullinan Oncology | Cullinan Oncology Price Prediction | Buy or Sell Advice |
Cullinan Oncology Forecasted Value
In the context of forecasting Cullinan Oncology's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Cullinan Oncology's downside and upside margins for the forecasting period are 9.55 and 16.84, respectively. We have considered Cullinan Oncology's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the 8 Period Moving Average forecasting method's relative quality and the estimations of the prediction error of Cullinan Oncology stock data series using in forecasting. Note that when a statistical model is used to represent Cullinan Oncology stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 103.3484 |
| Bias | Arithmetic mean of the errors | 0.4535 |
| MAD | Mean absolute deviation | 0.7205 |
| MAPE | Mean absolute percentage error | 0.0482 |
| SAE | Sum of the absolute errors | 38.1888 |
Predictive Modules for Cullinan Oncology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cullinan Oncology LLC. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cullinan Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Other Forecasting Options for Cullinan Oncology
For every potential investor in Cullinan, whether a beginner or expert, Cullinan Oncology's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Cullinan Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Cullinan. Basic forecasting techniques help filter out the noise by identifying Cullinan Oncology's price trends.View Cullinan Oncology Related Equities
| Risk & Return | Correlation |
Cullinan Oncology LLC Technical and Predictive Analytics
The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of Cullinan Oncology's price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of Cullinan Oncology's current price.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Cullinan Oncology Market Strength Events
Market strength indicators help investors to evaluate how Cullinan Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cullinan Oncology shares will generate the highest return on investment. By undertsting and applying Cullinan Oncology stock market strength indicators, traders can identify Cullinan Oncology LLC entry and exit signals to maximize returns.
Cullinan Oncology Risk Indicators
The analysis of Cullinan Oncology's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Cullinan Oncology's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting cullinan stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.87 | |||
| Standard Deviation | 3.63 | |||
| Variance | 13.18 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Historical Fundamental Analysis of Cullinan Oncology to cross-verify your projections. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.